Cervical cancer remains a significant global health concern, but with the advancement of preventive measures such as screening methods and vaccinations, there is hope for reducing its incidence and mortality rates. Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 604,000 new cases and 342,000 deaths reported in 2020 alone, according to the World Health Organization (WHO). However, a substantial portion of these cases could be prevented through early detection and vaccination against human papillomavirus (HPV), the primary cause of cervical cancer.
Screening for cervical cancer has been a cornerstone in the fight against this disease. The most widely used screening method is the Papanicolaou (Pap) test, which involves collecting cells from the cervix to detect any abnormalities that may indicate the presence of pre-cancerous or cancerous changes. Another effective screening method is the HPV test, which detects the presence of high-risk HPV strains known to cause cervical cancer. Both tests are essential tools in identifying cervical abnormalities at early stages when they are most treatable.
